Session Information
2007 BIO International Convention
Click here to go to the previous page
Valuation Challenges in Licensing and M&A
Track : Business Development
Program Code: BUS080
Date: Tuesday, May 8, 2007
Time: 4:00 PM to 5:30 PM  
Location: 206 AB
CHAIR :
Jeff Greene, Americas Pharmaceuticals Transaction Executive, Ernst & Young
SPEAKER (S):
David Piacquad, Senior Vice President Business Development, Schering-Plough
Harry Hamill, Vice President Corporate Strategic Projects, Wyeth Pharmaceuticals Inc.
Jason Amello, Vice President Strategic Financial Services, Genzyme Corporation
Mark Edwards, Managing Director, Recombinant Capital
Description
As transaction volumes and competition rise, corporate resources are increasingly challenged to perform the rigorous modeling and valuation analysis necessary to support executive decisions. Panelists will provide practical advice on the managerial and technical issues that are central to growth and efficient capital allocation in today's active deal environment.



Objectives:
  • Establish metrics for board and senior management approval.

  • Assess the value of early-stage candidates and pipelines.

  • Manage virtual deal teams that draw from across the company and external advisers.


  • Streaming Audio with
    PowerPoint Slides
    (Code: BUS080)
      
    This session is a part of: